WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1994025057) KGF RECEPTOR-DERIVED ANTAGONISTS OF KGF BINDING
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1994/025057    International Application No.:    PCT/US1994/004855
Publication Date: 10.11.1994 International Filing Date: 03.05.1994
Chapter 2 Demand Filed:    11.11.1994    
IPC:
A61K 38/00 (2006.01), C07K 14/71 (2006.01)
Applicants: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Box OTT, Bethesda, MD 20892 (US)
Inventors: BOTTARO, Donald, P.; (US).
RUBIN, Jeffrey, S.; (US).
AARONSON, Stuart, A.; (US)
Agent: BASTIAN, Kevin, L.; Townsend and Townsend Khourie and Crew, Steuart Street Tower, 20th Floor, One Market Plaza, San Francisco, CA 94105 (US)
Priority Data:
08/059,030 04.05.1993 US
Title (EN) KGF RECEPTOR-DERIVED ANTAGONISTS OF KGF BINDING
(FR) ANTAGONISTES DE LA LIAISON DU KGF DERIVES DU RECEPTEUR DE KGF
Abstract: front page image
(EN)The invention provides KGFR peptides which inhibit binding between keratinocyte growth factor (KGF) and its receptor. The sequence of the peptides is derived from regions in the receptor which specifically bind the growth factor. Also provided are pharmaceutical compositions and methods of inhibiting the interaction of KGF and the receptor in a patient to treat various carcinomas.
(FR)L'invention porte sur des peptides récepteurs du KGF (facteur de croissance des kératinocytes) inhibiteurs de la liaison entre le KGF et son récepteur. La séquence des peptides dérive de régions du récepteur qui se fixent spécifiquement au facteur de croissance. L'invention porte également sur des composés pharmaceutiques et des méthodes inhibant l'interaction du KGF et du récepteur chez un patient pour le traitement de différents carcinomes.
Designated States: AU, CA, JP.
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)